The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) securities between July 25, 2023 and August 6, 2026, inclusive (“the Class Period”). If you suffered a loss on your CVRx investments, you have until January 8, 2027 to request lead plaintiff appointment.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

Investors are encouraged to fill out the contact form above or contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

What Is This Lawsuit About? The lawsuit alleges that CVRx made materially false and/or misleading statements and failed to disclose that: (i) to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act (“FCA”) and Anti-Kickback Statute (“AKS”); (ii) CVRx’s revenues were in part the product of such unlawful conduct and thus unsustainable; and (iii) the illegal sales and marketing activities increased the risk of criminal and civil liability.

On August 6, 2026, CVRx filed with the SEC a Quarterly Report on Form 10-Q, disclosing that, on May 14, 2026, the Company “received a civil investigative demand (‘CID’) from the U.S Department of Justice in connection with an investigation under the False Claims Act.” CVRx stated, “The CID requested information and documents regarding an investigation into whether we caused the submission of false claims to government health insurance programs by improperly marketing our device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs.” Additionally, the Company lowered its revenue guidance, citing challenges with sales force productivity. On this news, the price of CVRx shares declined by $3.55 per share, or approximately 60%, from $5.94 per share on August 6, 2026 to close at $2.39 on August 7, 2026.

[LEARN MORE ABOUT THE LAWSUIT]

The Lead Plaintiff Appointment Process. The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a class action lawsuit. Courts do not consider lead plaintiff applications submitted after the relevant deadline. If you choose to take no action, you may remain an absent class member. Learn more about the lead plaintiff process and eligibility requirements here. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.

[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]

What Should I Do? If you purchased or otherwise acquired CVRx securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110777309/en/